ADVANCE: Risk of Cardiovascular Disease and Diabetes in Treatment-Naive Patients Initiating Dolutegravir- or Efavirenz-Based ART

Expert-authored CCO slides on strategies encompassed by the Ending the HIV Epidemic Initiative, including prevention and rapid diagnosis and treatment

W. David Hardy, MD
Program Director David A. Wohl, MD Released: October 20, 2020

Expert-authored CCO slides on simplification to 2-drug ART, ART safety during pregnancy, ART and weight gain, and long-acting injectable ART

W. David Hardy, MD
Program Director Michelle S. Cespedes, MD, MS Released: October 20, 2020

CCO slides on ending the HIV epidemic in the United States via expanded testing, enhanced linkage to care, and rapid response to potential outbreaks

Lisa K. Fitzpatrick, MD, MPH, MPA David Malebranche, MD, MPH Released: October 7, 2020

Multimedia module from Clinical Care Options: HIV experts weigh in on selecting first-line ART and modifying ART for those with virologic suppression

Joseph J. Eron, Jr., MD
Program Director Princy N. Kumar, MD, FIDSA, MACP
Program Director Eric S. Daar, MD W. David Hardy, MD Babafemi Taiwo, MBBS Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: September 18, 2020 Expired: September 17, 2021

Choosing ART for a Newly Diagnosed Person (26 mins)

Switching ART in Virologically Suppressed Persons (19 mins)